Central Nervous System Lymphoma
📧 Sign up to get email alerts when something new happens for Central Nervous System Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 3]
A Phase 3 trial (IGNITE) comparing tirabrutinib against Rituximab/Temozolomide for relapsed/refractory primary central nervous system lympho…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. [Phase 2]
A Phase 2 clinical trial is evaluating maintenance therapy with lenalidomide and rituximab for patients with primary central nervous system …
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) [Phase 1]
Phase 1 clinical trial evaluating MB-CART19.1 cellular therapy for primary and secondary central nervous system lymphoma, currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) [Phase 1, Phase 2]
Open-label Phase 1/2 trial evaluating Emavusertib (CA-4948) in relapsed or refractory primary central nervous system lymphoma; currently rec…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants [Phase 1]
Phase 1 pharmacokinetics study of tirabrutinib in participants with hepatic impairment (mild to severe) compared with healthy controls to as…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating pomalidomide combined with an anti-PD-1 antibody and selinexor (PPS) in relapsed/refractory primary cent…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma [EARLY_Phase 1]
This is an early-phase pilot study of glucarpidase in patients with primary central nervous system lymphoma. The trial is currently active b…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma [Phase 2]
A Phase 2 trial is evaluating an Ibrutinib-based combination therapy for newly diagnosed primary central nervous system lymphoma in transpla…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma [Phase 1]
Phase 1 study evaluating the safety and feasibility of combining ibrutinib with immunochemotherapy (temozolomide, etoposide, doxorubicin lip…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) [Phase 2]
This update describes a Phase 2 study of tirabrutinib (ONO-4059) in patients with primary central nervous system lymphoma, including refract…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma [Phase 2]
Phase 2 study evaluating lisocabtagene maraleucel as first-line therapy for transplant-ineligible primary central nervous system lymphoma; s…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma [Phase 2]
This update reports results from a Phase 2 trial for newly diagnosed primary central nervous system lymphoma conducted by IELSG; the trial i…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma [Phase 3]
Clinical trial update for the Phase 3 OptiMATe study evaluating de-escalated induction treatment in primary central nervous system lymphoma;…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab [Phase 2]
A Phase 2 clinical trial is recruiting to evaluate epcoritamab in relapsed/refractory primary central nervous system lymphoma treated with l…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma [Phase 1]
Phase 1 clinical trial evaluating acalabrutinib in combination with durvalumab for patients with central nervous system lymphoma (primary an…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 3]
This is a Phase 3 clinical trial (IGNITE) evaluating tirabrutinib against Rituximab/Temozolomide in relapsed/refractory primary central nerv…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma [Phase 1, Phase 2]
Acalabrutinib is being studied as maintenance therapy in a Phase 1/2 trial for large B-cell lymphomas, including diffuse large B-cell lympho…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort) [Phase 2]
This is a Phase 2 multicenter observational study enrolling treatment-naive primary central nervous system lymphoma patients to compare a re…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas [Phase 2]
A Phase 2 clinical trial is evaluating the combination of zanubrutinib and pemetrexed for relapsed or refractory primary and secondary centr…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Pembrolizumab, Ibrutinib and Rituximab in PCNSL [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study of pembrolizumab, ibrutinib, and rituximab in primary central nervous system ly…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Acalabrutinib in CNSL [Phase 1, Phase 2]
Acalabrutinib is being studied in a Phase 1/2 trial for Central Nervous System Lymphoma, including refractory and recurrent CNS lymphoma. Th…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL [Phase 1]
A Phase 1 study evaluating pembrolizumab in combination with chemotherapy for newly diagnosed Primary Central Nervous System Lymphoma is cur…